Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19538173rdf:typepubmed:Citationlld:pubmed
pubmed-article:19538173lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:19538173lifeskim:mentionsumls-concept:C0028128lld:lifeskim
pubmed-article:19538173lifeskim:mentionsumls-concept:C0033262lld:lifeskim
pubmed-article:19538173lifeskim:mentionsumls-concept:C1611640lld:lifeskim
pubmed-article:19538173lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:19538173lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:19538173pubmed:issue7lld:pubmed
pubmed-article:19538173pubmed:dateCreated2009-10-5lld:pubmed
pubmed-article:19538173pubmed:abstractTextNitric oxide (NO) prodrugs of the diazeniumdiolate class are routinely used as reliable sources of nitric oxide in chemical and biological laboratory settings. O(2)-(2,4-dinitrophenyl) diazeniumdiolates, which are derivatized forms of ionic diazeniumdiolates, have been found to show potent anti-proliferative activity in a variety of cancer cells, presumably through the effects of NO. One important member of this class of diazeniumdiolates, O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K), has shown promise as a novel cancer therapeutic agent in a number of animal models. This review describes the developments in chemical and biochemical characterization and structure-activity relationship of JS-K and its analogues. In addition, some molecular mechanistic insights into the observed anti-proliferative activity of JS-K are discussed. Finally, a structural motif is presented for O(2)-(aryl) diazeniumdiolate nitric oxide prodrugs that show potency comparable with that of JS-K.lld:pubmed
pubmed-article:19538173pubmed:languageenglld:pubmed
pubmed-article:19538173pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:citationSubsetIMlld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19538173pubmed:statusMEDLINElld:pubmed
pubmed-article:19538173pubmed:monthSeplld:pubmed
pubmed-article:19538173pubmed:issn1875-5992lld:pubmed
pubmed-article:19538173pubmed:authorpubmed-author:SaavedraJosep...lld:pubmed
pubmed-article:19538173pubmed:authorpubmed-author:ChakrapaniHar...lld:pubmed
pubmed-article:19538173pubmed:authorpubmed-author:MaciagAnna...lld:pubmed
pubmed-article:19538173pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19538173pubmed:volume9lld:pubmed
pubmed-article:19538173pubmed:ownerNLMlld:pubmed
pubmed-article:19538173pubmed:authorsCompleteYlld:pubmed
pubmed-article:19538173pubmed:pagination798-803lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:meshHeadingpubmed-meshheading:19538173...lld:pubmed
pubmed-article:19538173pubmed:year2009lld:pubmed
pubmed-article:19538173pubmed:articleTitleThe nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.lld:pubmed
pubmed-article:19538173pubmed:affiliationBasic Science Program, SAIC-Frederick, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA. amaciag@ncifcrf.govlld:pubmed
pubmed-article:19538173pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19538173pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19538173lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19538173lld:pubmed